Vaxart
Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in the discovery and development of oral recombinant protein vaccines using its proprietary oral vaccine platform. The company’s pipeline includes several oral tablet vaccines targeting norovirus, seasonal influenza, respiratory syncytial virus (RSV), and a therapeutic vaccine for human papillomavirus (HPV). Vaxart's vaccines are designed to elicit broad and durable immune responses, with the advantage of being administered as room temperature-stable tablets, which may enhance distribution and increase vaccination rates. Additionally, Vaxart is developing antiviral treatments, including teslexivir, aimed at specific viral infections. The company also collaborates with Janssen Vaccines & Prevention B.V. to explore the application of its oral vaccine platform for a universal influenza vaccine program.
Aviragen Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of treatments for serious infectious diseases. The company is advancing two Phase 2 clinical-stage product candidates: laninamivir octanoate, aimed at treating influenza A and B infections in the United States, supported by a contract with the U.S. Office of Biomedical Advanced Research and Development Authority. The second candidate, vapendavir, is an oral broad-spectrum capsid inhibitor targeting enteroviruses, including human rhinovirus. In addition to these programs, Aviragen has preclinical efforts focused on developing therapies for respiratory syncytial virus and is exploring treatments for human rhinovirus infections in patients with moderate-to-severe asthma, as well as antiviral options for condyloma caused by human papillomavirus.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.